Skip to main content
SpringerLink
Log in

The effect of bromocriptine treatment on sexual functioning and depressive symptoms in women with mild hyperprolactinemia

  • Original article
  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

Background

Elevated prolactin levels are associated with sexual dysfunction in women. No previous study has investigated the effect of dopamine agonists on sexual functioning in women.

Methods

The study enrolled 30 young women with mild hyperprolactinemia (serum prolactin levels in the range between 25 and 50 ng/mL), 15 of whom were later treated with bromocriptine (5–10 mg daily), as well as 14 age- and weight-matched healthy women. All women completed a questionnaire evaluating female sexual function (Female Sexual Function Index — FSFI) and a questionnaire evaluating the presence and severity of depressive symptoms (Beck Depression Inventory Second Edition — BDI-II).

Results

Women with mild hyperprolactinemia had a lower total FSFI score, lower scores in all domains of sexual functioning (desire, arousal, lubrication, and dyspareunia), as well as a lower total BDI-II score than control women. Bromocriptine increased the FSFI score and tended to reduce BDI-II score. Moreover, the drug normalized desire, arousal, lubrication and dyspareunia, as well as improved orgasm and sexual satisfaction and this action correlated with changes in prolactin levels and an improvement in insulin sensitivity. No changes in sexual functioning and depressive symptoms were observed in untreated women with mild hyperprolactinemia and healthy controls.

Conclusions

Bromocriptine treatment improves female sexual functioning and slightly affects depressive symptoms in women with elevated prolactin levels and this effect is related to its prolactin-lowering and metabolic effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

BDI-II:

Beck Depression Inventory-Second Edition

FSFI:

female sexual function index

HDL:

high-density lipoprotein

HOMA1-IR:

the homeostatic model 1 for insulin resistance index

LDL:

low-density lipoprotein

SD:

standard deviation

References

  1. Krüger TH, Haake P, Hartmann U, Schedlowski M, Exton MS. Orgasm-induced prolactin secretion: feedback control of sexual drive? Neurosci Biobehav Rev 2002;26:31–44.

    Article  Google Scholar 

  2. Kruger TH, Leeners B, Naegeli E, Schmidlin S, Schedlowski M, Hartmann U, et al. Prolactin secretory rhythm in women: immediate and long-term alterations after sexual contact. Hum Reprod 2012;27:1139–43.

    Article  CAS  Google Scholar 

  3. Leeners B, Krüger TH, Brody S, Schmidlin S, Naegeli E, Egli M. The quality of sexual experience in women correlates with post-orgasmic prolactin surges: results from an experimental prototype study. J Sex Med 2013;10:1313–9.

    Article  Google Scholar 

  4. Brody S, Krüger TH. The post-orgasmic prolactin increase following intercourse is greater than following masturbation and suggests greater satiety. Biol Psychol 2006;71:312–5.

    Article  Google Scholar 

  5. Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med 2009;6:1457–66.

    Article  CAS  Google Scholar 

  6. Corona G, Mannucci E, Petrone L, Giommi R, Mansani R, Fei L, et al. Psychobiological correlates of hypoactive sexual desire in patients with erectile dysfunction. IntJ Impot Res 2004;16:275–81.

    Article  CAS  Google Scholar 

  7. Kadioglu P, Yalin AS, Tiryakioglu O, Gazioglu N, Oral G, Sanli O, et al. Sexual dysfunction in women with hyperprolactinemia: a pilot study report. J Urol 2005;174:1921–5.

    Article  Google Scholar 

  8. Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, Okopien B. Sexual function and depressive symptoms in young women with elevated macroprolactin content: a pilot study. Endocrine 2016;53:291–8.

    Article  CAS  Google Scholar 

  9. Iván G, Szigeti-Csúcs N, Oláh M, Nagy GM, Góth MI. Treatment of pituitary tumors: dopamine agonists. Endocrine 2005;28:101–10.

    Article  Google Scholar 

  10. De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998;138:286–93.

    Article  Google Scholar 

  11. Ambrosi B, Bara R, Faglia G. Bromocriptine in impotence. Lancet 1977;2:987.

    Article  CAS  Google Scholar 

  12. Krüger TH, Haake P, Haverkamp J, Krämer M, Exton MS, Saller B, et al. Effects of acute prolactin manipulation on sexual drive and function in males. J Endocrinol 2003;179:357–65.

    Article  Google Scholar 

  13. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The female sexual function index (FSFI): a multidimensional selfreport instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.

    Article  CAS  Google Scholar 

  14. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cut-off scores. J Sex Marital Ther 2005;31:1–20.

    Article  Google Scholar 

  15. Beck AT, Steer RA, Brown GK. BDI-II: Beck Depression Inventory Manual. 2nd ed. San Antonio: Psychological Corporation; 1996.

    Google Scholar 

  16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders—DSM-IV-TR. 4th ed. Washington: American Psychiatric Publishing; 1994.

    Google Scholar 

  17. dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 2011;19:800–5.

    Article  Google Scholar 

  18. Berinder K, Nyström T, Höybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011;14:199–207.

    Article  CAS  Google Scholar 

  19. Jiang XB, He DS, Mao ZG, Fan X, Lei N, Hu B, et al. BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort. Tumour Biol 2013;34:1171–6.

    Article  CAS  Google Scholar 

  20. Krysiak R, Okopień B. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin Pharmacol Toxicol 2015;116:251–6.

    Article  CAS  Google Scholar 

  21. Hattori N, Ishihara T, Saiki Y. Macroprolactinemia prevalence and aetiologies in a large group of hospital workers. Clin Endocrinol (Oxf) 2009;71:702–8.

    Article  Google Scholar 

  22. Fahie-Wilson M, Smith TP. Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocrinol Metab 2013;27:725–42.

    Article  CAS  Google Scholar 

  23. Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, Okopien B. Sexual function and depressive symptoms in young women with thyroid autoimmunity and subclinical hypothyroidism. Clin Endocrinol (Oxf) 2016;84:925–31.

    Article  CAS  Google Scholar 

  24. Prabhakar VK, Davis JR. Hyperprolactinaemia. Best Pract Res Clin Obstet Gynaecol 2008;22:341–53.

    Article  CAS  Google Scholar 

  25. Matera L, Mori M, Geuna M, Buttiglieri S, Palestro G. Prolactin in autoimmunity and antitumor defence. J Neuroimmunol 2000;109:47–55.

    Article  CAS  Google Scholar 

  26. Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Top Behav Neurosci 2013;14:135–51.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland

    Robert Krysiak, Witold Szkróbka & Bogusław Okopień

Authors
  1. Robert Krysiak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Witold Szkróbka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bogusław Okopień
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Krysiak.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krysiak, R., Szkróbka, W. & Okopień, B. The effect of bromocriptine treatment on sexual functioning and depressive symptoms in women with mild hyperprolactinemia. Pharmacol. Rep 70, 227–232 (2018). https://doi.org/10.1016/j.pharep.2017.10.008

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.pharep.2017.10.008

Keywords

Search

Navigation